

**RECEIVED  
CENTRAL FAX CENTER****MAY 31 2005****GlaxoSmithKline****FAX**

**To** Art Unit 1614  
.....  
**Company** USPTO  
.....  
**Fax** (703) 872-9306  
.....  
**From** Valerie L. Phillips  
.....  
**Tel** 919-483-8223 **Fax** 919-483-5730  
.....  
**E-mail** valerie.l.phillips@gsk.com  
.....  
**Date** May 31, 2005 **Pages including cover** 14  
.....  
**Subject** Supplemental IDS  
.....

Glaxo Wellcome Inc.  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709  
Tel: 919 483 2100  
www.gsk.com

**Serial No.:** 10/502,266  
**Date:** March 17, 2005  
**Applicant:** Alvaro et al.  
**Title:** PIPERIDYL CARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKININ-MEDIATED DISEASES

Attached:  
Supplemental IDS  
PTO 1449  
1 Reference  
Certificate of Transmission by Facsimile

**Certificate of Transmission by Facsimile (37 CFR 1.8)**

I hereby certify that this Supplemental IDS is being facsimile transmitted to the United States Patent and Trademark Office (Fax, No. 703-872-9306) on May 31, 2005

*Valerie L. Phillips*  
\_\_\_\_\_  
Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Atty. Docket No. PI4749Usw

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE: Application of Alvaro et al.

Serial No.: 10/502,266

Art Unit: 1614

Filing Date: March 17, 2005

Examiner: To be Assigned

For: PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF  
TACHYKININ-MEDIATED DISEASES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_  
(37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  
(1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311,  
whichever occurs first.

Atty. Docket No. PI4749Usw

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan  
Attorney of Record  
Registration No. 38,181

Date: 31 May 2005  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8222  
Facsimile: (919) 483-7988

